Accolade, Inc.: directors' dealings · United States · SEC (Form 4)

About Accolade, Inc.

Accolade, Inc. is a U.S.-based digital health company that was listed on the NASDAQ in the United States under the ticker ACCD. Historically, the business focused on healthcare navigation, patient advocacy, and helping employees and their families understand and use health benefits more effectively. Founded in 2009, Accolade built its model around a “Personalized Healthcare” approach that combines cloud-based technology, data, and human support from trained health assistants and clinicians to help members navigate a fragmented healthcare system. ([accolade.com](https://www.accolade.com/company/?utm_source=openai)) The company is headquartered in Seattle, Washington, United States, and its website also references additional offices in Pennsylvania, Houston, Prague, San Francisco, and Vancouver. While it has a multi-location footprint, Accolade’s core commercial focus has been North America, where it serves employers, health plans, and other buyers looking to improve care access, member experience, and administrative efficiency. ([accolade.com](https://www.accolade.com/company/?utm_source=openai)) Operationally, Accolade’s main business lines have centered on care delivery, health advocacy, expert medical opinions, and virtual primary care. The company’s platform is designed to blend technology with personalized human interaction, using digital tools, mobile access, online workflows, and phone-based support to guide members to the right care at the right time. That hybrid model has been a key differentiator versus more automated healthcare solutions, especially for employers seeking a single point of contact for benefits questions, care navigation, and clinical support. ([accolade.com](https://www.accolade.com/company/?utm_source=openai)) In terms of corporate development, Accolade launched in 2009, went public on NASDAQ in 2020, and then expanded through several strategic acquisitions, including PlushCare, 2nd.MD, MD Insider, and HealthReveal. In 2021, the company formally introduced the “Personalized Healthcare” category, reinforcing its positioning as a broader care and navigation platform rather than a narrow benefits concierge service. Those moves helped Accolade broaden its product scope and deepen its relevance with self-insured employers and health plan clients. ([accolade.com](https://www.accolade.com/company/?utm_source=openai)) From a competitive standpoint, Accolade has competed in a crowded healthcare engagement and navigation market where differentiation depends on clinical credibility, member engagement, data integration, and measurable cost outcomes. The company has highlighted a sizable client and member base, which supported its scale position in the benefits navigation and advocacy segment. At the same time, the category is structurally competitive and operationally demanding, with pressure to prove ROI to enterprise buyers and to maintain service quality across a complex healthcare ecosystem. ([accolade.com](https://www.accolade.com/company/?utm_source=openai)) A major recent development occurred on April 8, 2025, when Transcarent announced the completion of its merger with Accolade for approximately $621 million. The announcement stated that Accolade’s common stock would no longer be listed on NASDAQ and that the company had become part of a privately held combined group. For investors tracking SEC Form 4 insider transactions, that is an important context point: Accolade’s public-market profile changed materially after the transaction closed. ([accolade.com](https://www.accolade.com/resources/transcarent-completes-merger-with-accolade?utm_source=openai))